BMS’s updated disclosure about a fatal septic pneumonia event in its zola-cel MS CAR T program adds another datapoint to the evolving safety landscape across CAR T development in CNS indications. While BMS stated it cannot identify causality and described the motor symptoms as late-onset, it also noted that cytokine release syndrome occurred in just under half of patients. The update follows prior trial pauses tied to competitor events earlier in the year and underscores the need for consistent adverse-event capture and full case review protocols as studies expand. For the sector, the practical effect is tighter scrutiny around infection risk windows and the confounding role of heavy pretreatment, which may influence inclusion criteria and supportive care plans in subsequent trials.